Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Translational Sciences Inc
Profile last edited on: 5/27/2022      CAGE: 4TVM7      UEI: EFQDNXDDTBM4

Business Identifier: Biopharmaceuticals for treatment of acute cardiovascular diseases and ischemic stroke
Year Founded
2010
First Award
2010
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1840 Overton Park Avenue
Memphis, TN 38112
   (901) 274-4506
   N/A
   www.translationalsciences.com
Location: Single
Congr. District: 09
County: Shelby

Public Profile

Translational Sciences Inc. is developing biopharmaceuticals for the treatment of acute cardiovascular disaeses and ischemic stroke. The principal of the firm is Diggs Professor and chairman of the Department of Medicine for the University of Tennessee Health Science Center (UTHSC).

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
5
Conversion Rate
100.00%
Phase I Dollars
$855,006
Phase II Dollars
$15,974,408
Total Awarded
$16,829,414

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $2,780,397
Project Title: Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke
2021 2 NIH $2,817,682
Project Title: Novel ?2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
2021 2 NIH $6,659,126
Project Title: Reducing Stroke by a Novel, Clot-dissolving Antibody
2020 2 NIH $3,163,119
Project Title: Hls Potent, Novel Inhibitor of Fibrinolytic Hemorrhage
2015 2 NIH $2,692,125
Project Title: Novel Methods for Dissolving Blood Clots

Key People / Management

  Sun Yong Jeong

  Paul H Kussie

  Guy L Reed -- Principal

Company News

There are no news available.